研究者詳細 - 中永　士師明

研究等業績 - 原著論文 - 中永　士師明

分割表示 85 件中 1 - 20 件目／全件表示 >>

Conventional and Kampo Medicine Treatment for Mild-to-moderate COVID-19: A Multicenter, Retrospective, Observational Study by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-Observation)

Takayama Shin, Yoshino Tetsuhiro, Koizumi Sayaka, Irie Yasuhito, Suzuki Tomoko, Fujii Susumu, Katori Rie, Kainuma Mosaburo, Kobayashi Seiichi, Nogami Tatsuya, Yokota Kenichi, Yamazaki Mayuko, Minakawa Satoko, Chiba Shigeki, Suda Norio, Nakada Yoshinobu, Ishige Tatsuya, Maehara Hirofumi, Tanaka Yutaka, Nagase Mahiko, Kashio Akihiko, Komatsu Kazuhisa, Nojiri Makoto, Shimooki Osamu, Nakamoto Kayo, Arita Ryutaro, Ono Rie, Saito Natsumi, Kikuchi Akiko, Ohsawa Minoru, Nakae Hajime, Mitsuma Tadamichi, Mimura Masaru, Ishii Tadashi, Nochioka Kotaro, Chiu Shih-Wei, Yamaguchi Takuhiro, Namiki Takao, Hisanaga Akito, Mitani Kazuo, Ito Takashi

Japanese Journal of Medicine ( 一般社団法人日本内科学会 ) advpub ( 0 ) 187 - 199 2023年 [査読有り]

研究論文（学術雑誌）国内共著

Objective Patients in whom coronavirus disease 2019 (COVID-19) was suspected or confirmed between January 1, 2020, and October 31, 2021, were enrolled from Japanese hospitals in this multicenter, retrospective, observational study. Methods Data on the treatment administered (including conventional and Kampo medicine) and changes in common cold-like symptoms (such as fever, cough, sputum, dyspnea, fatigue, and diarrhea) were collected from their medical records. The primary outcome was the number of days without a fever (with a body temperature <37 °C). The secondary outcomes were symptomatic relief and the worsening of illness, defined as the presence of a condition requiring oxygen inhalation. The outcomes of patients treated with and without Kampo medicine were compared. Patients We enrolled 962 patients, among whom 528 received conventional and Kampo treatment (Kampo group) and 434 received conventional treatment (non-Kampo group). Results Overall, after adjusting for the staging of COVID-19 and risk factors, there were no significant between-group differences in the symptoms or number of days being afebrile. After performing propensity score matching and restricting the included cases to those with confirmed COVID-19 who did not receive steroid administration and initiated treatment within 4 days from the onset, the risk of illness worsening was significantly lower in the Kampo group than in the non-Kampo group (odds ratio=0.113, 95% confidence interval: 0.014-0.928, p=0.0424). Conclusion Early Kampo treatment may suppress illness worsening risk in COVID-19 cases without steroid use. Further randomized controlled studies are needed to confirm the clinical benefit of Kampo medicine for COVID-19.

DOI PubMed CiNii Research

A case of adverse skin reactions to coronavirus disease 2019 vaccine successfully treated with eppikajutsuto

Kameyama Koumei, Nakae Hajime, Irie Yasuhito

Personalized Medicine Universe ( 一般社団法人国際個別化医療学会 ) 11 ( 0 ) 20 - 22 2022年11月 [査読有り]

研究論文（学術雑誌）国内共著

Adverse skin reactions to coronavirus disease 2019 (COVID-19) vaccines have been rare. Because eppikajutsuto (EPTJ), which can alleviate inflammatory swelling, has heatTraditional Medicine module 1 (TM1)-clearing and fluidTM1-regulating potentials, we used it in a case of adverse skin reactions to COVID-19 vaccine. A 35-year-old woman received the second COVID-19 vaccine and presented with hacking, headache, and red glow on the face soon after receiving the vaccine. Symptoms such as flushing and wheal on the upper body improved after treatment with EPTJ. EPTJ can be used to alleviate the symptoms of adverse skin reactions to COVID-19 vaccines.

DOI CiNii Research

Application of Traditional Japanese Drug Jidabokuippo in a Modern Society

Nakae H.

Frontiers in Pharmacology ( Frontiers in Pharmacology ) 13 2022年05月 [査読有り]

研究論文（学術雑誌）国内共著

<中永 士師明>

研究等業績 - 原著論文 - 中永 士師明

<中永　士師明>

研究等業績 - 原著論文 - 中永　士師明